Clinical trials: Bendamustine, completed
Follicular Non-Hodgkin's Lymphoma
Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Recently, the availability of R has substantially changed therapeutic approach to FL patients, since its combination with chemotherapy has improved response rates, progression free survival (PFS) and overall survival (OS).
- Trial name
- NCT02063685
- Testing
- R-CHOP or R-bendamustine, Observation, Maintenance weekly x4
- Where
- 48 sites in Italy
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Waldenstrom's Macroglobulinemia
Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of Bortezomib plus Rituximab plus Bendamustine in patients with relapsed/refractory Waldenstrom's Macroglobulinemia.
- Trial name
- FIL_BRB (NCT02371148)
- Testing
- Bortezomib-Rituximab-Bendamustine
- Where
- 23 sites in Italy
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS